Kelyniam Maintains the position of Full Disclosure with the public and all regulatory bodies. 

With our policy of keeping our investors informed, the company's financials and share structure will be released to the public on a continuous basis.  Please refer to the link provided on our Web Pages directing you to all of the Company's SEC Filings and Financial Statements and our Financial Statements on our Website.

Kelyniam Global, Inc. welcomes all correspondence and questions from investors and potential investors. We promise to respond to your questions in a timely fashion.

The company stock currently trades under the ticker symbol KLYG.

A letter from our CEO, Mr. James Ketner:  12/12/08

"I would like to take a little time to discuss Kelyniam's management philosophy, and some of our accomplishments, and some of our future goals.  We incorporated in December 2005, and went public in April 2008 somewhat as a shell company.  Since going public, we acquired M2-Systems in New Britain Connecticut, which immediately gave the company assets and revenues.  Kelyniam is no longer a shell company.  We are growing, and we have some very exciting new projects in the works.  Our second quarter revenues for 2008 were about $160,000 USD, which is more than the company had done since inception in 2005 through the end of first quarter 2008.  Our third quarter 2008 revenues were $188,000, which is a 17% increase in revenues quarter over quarter.  Not spectacular, but gives a pattern of the type of growth rate management is anticipating over the next 2 years.  This type of growth rate does not include any new acquisitions, or the Food and Drug administration approving the process for our cranial implants.  When the FDA does approve the artificial bone replacement process, then we can expect greater growth rates than above mentioned.  I say that with much confidence because we believe in the process adamantly.  This type of technology will be the future of medicine.

During the third quarter 2008, the company received a technology research grant from the state of Connecticut.  Kelyniam used the proceeds from this grant to advance our abilities in the reproduction of organic shapes.  Management believes the ability to reproduce organic shapes in extremely high tolerances will be key in the development of high precision medical advancements.

None of our officers are currently receiving a salary.  We have all agreed to "not get paid" until the company debt is gone.  All future monies raised by selling securities or generated by the company will be used for two things, paying off debt, and growing the business, none of which includes officer compensation.  These types of things would be important to me if I were considering investing in a small startup like Kelyniam.  When all debt is paid, and we can start showing retained earnings, then officer compensation will be considered.

The management of Kelyniam is committed to the shareholders, which could be viewed as us just being selfish, because the management at Kelyniam are significant shareholders.  Our future compensation will be dependent on the performance of the stock.  Our net worth, and our friends and families investments are dependent on the performance of Kelyniam's stock. All officers have resale restrictions in place that are dependent on continued employment, and become vested and mature on a yearly basis.  The resale restriction agreements can be viewed by following the link to our SEC filings, and are filed on form 8-K on May 29, 2008.

The management at Kelyniam intends on becoming fully reporting again after the company has grown enough to substantiate a stock price that would allow us to trade on an exchange higher than the OTC.BB.  From past experience, we do not feel there is any benefit at the moment by maintaining a fully reporting status for the company stock to trade on the OTC.BB.  We do however continually report our financial statements that would normally be required by the SEC and by a PCAOB accountant on form 10Q, and will be reporting our 2008 year end financials that would normally be necessary on form 10K.  These reports are and will be displayed on the company website by following the link 'Financials'.  Again, these are more things that would really be important to me if I were considering investing in a small startup company like ours.

Please contact our corporate office if you have addition questions about Kelyniam.

Thank you again for your time and consideration"

James Ketner